Peering into the darkness of drug-induced thrombotic microangiopathy: complement, are you in there?
作者信息
Sabulski Anthony, Jodele Sonata
机构信息
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
出版信息
J Gastrointest Oncol. 2023 Feb 28;14(1):468-471. doi: 10.21037/jgo-2022-04. Epub 2023 Jan 15.
Abstract
摘要
相似文献
1
Peering into the darkness of drug-induced thrombotic microangiopathy: complement, are you in there?窥探药物诱导的血栓性微血管病的黑暗：补体，你在其中吗？
J Gastrointest Oncol. 2023 Feb 28;14(1):468-471. doi: 10.21037/jgo-2022-04. Epub 2023 Jan 15.
2
Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report.依库珠单抗在儿童难治性吉西他滨诱导的血栓性微血管病中的作用：一例报告
J Med Case Rep. 2017 Jul 27;11(1):209. doi: 10.1186/s13256-017-1373-5.
3
The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.依库珠单抗在犬咬二氧化碳嗜纤维菌相关血栓性微血管病中的应用：一例报告
BMC Infect Dis. 2021 Feb 1;21(1):137. doi: 10.1186/s12879-021-05789-2.
4
Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.血栓性微血管病伴狼疮性肾炎时的替代补体途径激活。
Clin Rheumatol. 2021 Jun;40(6):2233-2242. doi: 10.1007/s10067-020-05499-1. Epub 2020 Nov 10.
5
Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.依库珠单抗单次剂量治疗吉西他滨相关性血栓性微血管病的快速改善：病例报告及文献复习。
Anticancer Res. 2020 Jul;40(7):3995-4000. doi: 10.21873/anticanres.14393.
6
[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: A case report].[依库珠单抗治疗吉西他滨诱导的血栓性微血管病的临床疗效：病例报告]
Rev Med Interne. 2016 Oct;37(10):701-704. doi: 10.1016/j.revmed.2015.12.027. Epub 2016 Jan 28.
7
A Case of Gemcitabine-Induced Thrombotic Microangiopathy Treated With Ravulizumab in a Patient With Stage IV Pancreatic Cancer.1例IV期胰腺癌患者使用ravulizumab治疗吉西他滨诱导的血栓性微血管病
Cureus. 2021 Jan 31;13(1):e13031. doi: 10.7759/cureus.13031.
8
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.长效C5抑制剂ravulizumab在未接受过补体抑制剂治疗的非典型溶血性尿毒症综合征成年患者中有效且安全。
Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6.
9
Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy.补体C5抑制可逆转博来霉素诱导的血栓性微血管病。
Clin Kidney J. 2020 Jul 9;14(4):1275-1276. doi: 10.1093/ckj/sfaa101. eCollection 2021 Apr.
10
Gemcitabine-induced thrombotic microangiopathy.吉西他滨诱导的血栓性微血管病。
Intern Med J. 2013 Nov;43(11):1240-2. doi: 10.1111/imj.12261.
引用本文的文献
1
A Case Report of Quinine-Induced Thrombotic Microangiopathy Successfully Treated With Eculizumab.奎宁诱导的血栓性微血管病成功用依库珠单抗治疗的 1 例报告。
J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241235617. doi: 10.1177/23247096241235617.
本文引用的文献
1
Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report.用依库珠单抗治疗吉西他滨诱导的血栓性微血管病：一例报告
J Gastrointest Oncol. 2022 Dec;13(6):3314-3320. doi: 10.21037/jgo-22-509.
2
Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.协调移植相关性血栓性微血管病的诊断标准和预后评估定义：欧洲血液和骨髓移植学会、美国移植和细胞治疗学会、亚太血液和骨髓移植学会以及国际血液和骨髓移植研究中心的报告。
Transplant Cell Ther. 2023 Mar;29(3):151-163. doi: 10.1016/j.jtct.2022.11.015. Epub 2022 Nov 25.
3
C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy.C5抑制可使癌症及化疗相关血栓性微血管病患者继续接受抗肿瘤治疗。
Blood Adv. 2022 Dec 13;6(23):6071-6074. doi: 10.1182/bloodadvances.2022008395.
4
Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients.移植相关性血栓性微血管病：阐明预防策略并确定高危患者。
Expert Rev Hematol. 2021 Aug;14(8):751-763. doi: 10.1080/17474086.2021.1960816. Epub 2021 Aug 4.
5
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.依库珠单抗治疗吉西他滨诱导的血栓性微血管病：法国血栓性微血管病参考中心的经验。
BMC Nephrol. 2021 Jul 21;22(1):267. doi: 10.1186/s12882-021-02470-3.
6
Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation.补体激活标志物sC5b-9早期升高作为干细胞移植后血栓性微血管病发生的预测生物标志物的验证
Front Med (Lausanne). 2020 Oct 6;7:569291. doi: 10.3389/fmed.2020.569291. eCollection 2020.
7
Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.依库珠单抗单次剂量治疗吉西他滨相关性血栓性微血管病的快速改善：病例报告及文献复习。
Anticancer Res. 2020 Jul;40(7):3995-4000. doi: 10.21873/anticanres.14393.
8
Eculizumab in chemotherapy-induced thrombotic microangiopathy.依库珠单抗治疗化疗诱导的血栓性微血管病。
Clin Nephrol Case Stud. 2020 Apr 17;8:25-32. doi: 10.5414/CNCS109836. eCollection 2020.
9
Eculizumab therapy in gemcitabine-induced thrombotic microangiopathy in a renal transplant recipient.依库珠单抗治疗肾移植受者吉西他滨诱导的血栓性微血管病
Oxf Med Case Reports. 2019 Jun 14;2019(6):omz048. doi: 10.1093/omcr/omz048. eCollection 2019 Jun.
10
Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management.儿童造血细胞移植受者的移植相关血栓性微血管病：诊断与管理的实用方法
Front Pediatr. 2019 Apr 9;7:133. doi: 10.3389/fped.2019.00133. eCollection 2019.
Zotero 插件